蒋白山｜武汉大学｜学者主页

2026

新型分子胶LTL-04-061通过CRBN介导的泛素-蛋白酶体通路靶向降解OTULIN并显著抑制胃癌细胞增殖

刘振昆，彭紫依，向俊宇，王斌，蒋白山，邱秋，李玉红

《陆军军医大学学报》

2026

Selective and Potent First‐in‐Class CRBN‐Dependent Molecular Glue Degraders of WW Domain‐Binding Protein 4

Yuhang Liu, Lu Chen, Bo Peng, Pei Zeng, Linhui Cao, Lu Huang, Lixin Zhou, Shuke Yang, Jun Wang, Yanli Sun, Lu Chen, Yixuan Feng, Taiting Shi, Qi Chen, Kehao Zhao, Jing Lu, Baishan Jiang, Wenchao Lu

Angewandte Chemie

DOI

2026

Discovery of WWZ-11-098: a rigid and selective CDK6 degrader

Wanwan Zhang, Jiaye Wen, Yuanyuan Wu, Yong Xuan, Qiangqiang Han, Xi Chen, Jingtian Yu, HaiJun Yu, Baishan Jiang

European Journal of Medicinal Chemistry

DOI

2026

Abstract B048: CDK4/6 bifunctional degraders overcome CDK4/6i resistance in breast cancer and demonstrate antitumor efficacy in additional tumor types

Maechen Wang, Qing Li, Baishan Jiang, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Nathanael S. Gray, Sarat Chandarlapaty

Clinical Cancer Research

DOI

2026

Abstract PR013: CDK4/6 bifunctional degraders overcome CDK4/6i resistance in breast cancer and demonstrate antitumor efficacy in additional tumor types

Maechen Wang, Qing Li, Baishan Jiang, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Nathanael S. Gray, Sarat Chandarlapaty

Clinical Cancer Research

DOI

2026

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

Jiaye Wen, Jingtian Yu, Wuqiang Wen, Baishan Jiang

MedComm – Oncology

DOI

2026

A scalable, high-throughput glue perturbation screening platform for molecular glue discovery

Diyun Huang, Zeyu Shuang, Lu Chen, Hanyue Ouyang, Peiyu Yang, Lichang Huang, Wenchao Lu, Ming Shi, Xiaofan Ding, Baishan Jiang, Wenchao Wu

iScience

DOI

2025

Selective and Potent Molecular Glue Degraders for NIMA‐Related Kinase 7

Lu Chen, Lu Huang, Wuqiang Wen, Pei Zeng, Yuanyuan Wu, Qiangqiang Han, Xi Chen, Zhixiang Guo, Haijun Yu, Wenchao Lu, Baishan Jiang

Angewandte Chemie

DOI

2025

Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity

Linhui Cao, Jing Yang, Yuhang Liu, Xiaotong Chen, Yufang Shi, Yunshuo Zhao, Yong Zhang, Jian Chen, Bowen Li, Wuqiang Wen, Lu Chen, Bo Peng, Lu Hsiang Huang, Yanli Sun, Lixin Zhou, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Zhixiang Guo, Jing Xing, Guangya Zhu, Yazhou Wang, Baishan Jiang, Jing Nan Lu, Kehao Zhao, Wenchao Lu

Advanced Science

DOI

2025

Abstract 409: Targeted degradation of FAK and PYK2 in cancer

Christina C. Kuismi, Yuan Jiang, Baishan Jiang, Behnam Nabet

Cancer Research

DOI

2024

Development of Oral, Potent, and Selective CK1α Degraders for AML Therapy

Lu Huang, Lü Chen, Lü Chen, Xiaozhong Peng, Lixin Zhou, Yanli Sun, Taiting Shi, Jiayi Lu, Weiye Lin, Yuhang Liu, Linhui Cao, Lanlan Li, Qiangqiang Han, Xi Chen, Ping Yang, Shuo Zhang, Zhe Wang, Jing Yang, Zhixiang Guo, Baishan Jiang, Wenchao Lu

JACS Au

DOI

2023

PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies

Vishnu Muthuraj Kumarasamy, Zhe Gao, Bosheng Zhao, Baishan Jiang, Seth M. Rubin, Kevin Burgess, Agnieszka Katarzyna Witkiewicz, Erik S. Knudsen

British Journal of Cancer

DOI

2023

Front Cover: Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity (ChemBioChem 19/2023)

Eriko Koide, Mikaela L. Mohardt, Zainab M. Doctor, Annan Yang, Mingfeng Hao, Katherine A. Donovan, Christina C. Kuismi, Alissa J. Nelson, Kathryn Abell, Mike Aguiar, Jianwei Che, Matthew P. Stokes, Tinghu Zhang, Andrew J. Aguirre, Eric S. Fischer, Nathanael S. Gray, Baishan Jiang, Behnam Nabet

ChemBioChem

DOI

蒋白山

精选作品

期刊论文

新型分子胶LTL-04-061通过CRBN介导的泛素-蛋白酶体通路靶向降解OTULIN并显著抑制胃癌细胞增殖

Selective and Potent First‐in‐Class CRBN‐Dependent Molecular Glue Degraders of WW Domain‐Binding Protein 4

Discovery of WWZ-11-098: a rigid and selective CDK6 degrader

Abstract B048: CDK4/6 bifunctional degraders overcome CDK4/6i resistance in breast cancer and demonstrate antitumor efficacy in additional tumor types

Abstract PR013: CDK4/6 bifunctional degraders overcome CDK4/6i resistance in breast cancer and demonstrate antitumor efficacy in additional tumor types

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

A scalable, high-throughput glue perturbation screening platform for molecular glue discovery

Selective and Potent Molecular Glue Degraders for NIMA‐Related Kinase 7

Discovery of a Potent and Selective TEAD Degrader with Durable Degradation Activity

Abstract 409: Targeted degradation of FAK and PYK2 in cancer

Development of Oral, Potent, and Selective CK1α Degraders for AML Therapy

PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies

Front Cover: Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity (ChemBioChem 19/2023)

研究方向